Grisay Guillaume, Turco Fabio, Litiere Saskia, Fournier Béatrice, Patrikidou Anna, Gallardo Enrique, McDermott Ray, Alanya Ahu, Gillessen Silke, Tombal Bertrand
Department of Medical Oncology, Centres Hospitaliers Universitaires HELORA, La Louvière, Belgium.
Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
Front Oncol. 2024 May 8;14:1391825. doi: 10.3389/fonc.2024.1391825. eCollection 2024.
The landscape of treating metastatic prostate cancer has evolved with the addition of Androgen Receptor pathway inhibitor (ARPI) to Androgen Deprivation Therapy (ADT), significantly improving survival rates. However, prolonged use of these therapies introduces notable side effects, prompting a need to revisit intermittent treatment duration. The EORTC 2238 De-Escalate trial is a pragmatic trial seeking to reassess the role of intermittent therapy in patients undergoing maximal androgen blockade (MAB) for metastatic hormone naïve prostate cancer (mHNPC), i.e., the combination of ADT with an ARPI, with the aims of reducing side effects, enhancing Quality of Life (QoL) and optimizing resource usage, while maintaining oncological benefits.
随着雄激素受体通路抑制剂（ARPI）被添加到雄激素剥夺疗法（ADT）中，转移性前列腺癌的治疗格局发生了变化，显著提高了生存率。然而，长期使用这些疗法会带来明显的副作用，这促使人们需要重新审视间歇性治疗的时长。欧洲癌症研究与治疗组织（EORTC）2238降阶梯试验是一项务实的试验，旨在重新评估间歇性疗法在接受最大雄激素阻断（MAB）治疗的初治转移性激素敏感性前列腺癌（mHNPC）患者中的作用，即ADT与ARPI联合使用，目的是减少副作用、提高生活质量（QoL）并优化资源利用，同时保持肿瘤学益处。
